ARTICLE | Strategy
Pathfinding for access
Novartis’ pathfinding value-based deal with CMS for CAR T therapy Kymriah
September 2, 2017 12:59 AM UTC
A pact with the Centers for Medicare & Medicaid Services for Novartis AG’s CAR T therapy demonstrates leadership in new value-based drug pricing models.
Kymriah tisagenlecleucel represents a milestone for three reasons. Its approval by FDA on Aug. 30 was the first for a chimeric antigen receptor T cell therapy. It was the first therapy to show a durable response in pediatric and young adult patients with relapsed, refractory B cell acute lymphoblastic leukemia (ALL) who are out of options...